APLT Applied Therapeutics, Inc.

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

$17.69  -1.23 (-6.50%)
As of 03/04/2021 15:59:13 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Small cap
Health Care
Biotechnology
USA
USA
05/08/2019
25,493,661
173,847
$482,340,066
0.00%
SEC Edgar Online
10-Q
10-K
03828A101
US03828A1016
BJL38Z1

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
10.55
0.00
-85.39%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy